TY - JOUR
T1 - Magnitude and determinants of CD4 recovery after haart resumption after 1 cycle of treatment interruption
AU - Mussini, Cristina
AU - Touloumi, Giota
AU - Bakoyannis, Giorgos
AU - Sabin, Caroline
AU - Castagna, Antonella
AU - Sighinolfi, Laura
AU - Erikson, Lars E.
AU - Bratt, Goran
AU - Borghi, Vanni
AU - Lazzarin, Adriano
AU - Cossarizza, Andrea
AU - Esposito, Roberto
PY - 2009/12
Y1 - 2009/12
N2 - OBJECTIVE: The extent of immune reconstitution following HAART resumption after 1 cycle of treatment interruption (TI) is not well known. METHODS: Multicenter retrospective analysis of patients who discontinued HAART with a CD4 > 500 cells/μL. Cox proportional hazards models were used to identify prognostic factors for immunologic response after treatment resumption. CD4 trends were investigated using linear mixed models. RESULTS: One hundred and eighty-three individuals were included. Median CD4 at TI and at treatment restart were 748 and 459 cells/μL, respectively. Median time from TI to treatment restart was 5.52 months. Ninety percent of the patients reached an undetectable viral load. One hundred and twenty-five subjects experienced immunologic response; 66 patients reached their pre-TI CD4 levels. At 3, 6, 12, and 24 months after treatment restart, the median CD4 increase was 149, 153, 161, and 178 cells/μL, respectively. Subjects with less steep CD4 declines during TI tended to have a lower initial CD4 increase, as did those reinitiating HAART with viral loads
AB - OBJECTIVE: The extent of immune reconstitution following HAART resumption after 1 cycle of treatment interruption (TI) is not well known. METHODS: Multicenter retrospective analysis of patients who discontinued HAART with a CD4 > 500 cells/μL. Cox proportional hazards models were used to identify prognostic factors for immunologic response after treatment resumption. CD4 trends were investigated using linear mixed models. RESULTS: One hundred and eighty-three individuals were included. Median CD4 at TI and at treatment restart were 748 and 459 cells/μL, respectively. Median time from TI to treatment restart was 5.52 months. Ninety percent of the patients reached an undetectable viral load. One hundred and twenty-five subjects experienced immunologic response; 66 patients reached their pre-TI CD4 levels. At 3, 6, 12, and 24 months after treatment restart, the median CD4 increase was 149, 153, 161, and 178 cells/μL, respectively. Subjects with less steep CD4 declines during TI tended to have a lower initial CD4 increase, as did those reinitiating HAART with viral loads
KW - HAART resumption
KW - HIV infection
KW - Immunological response
KW - Prognostic factors
KW - Treatment interruption
KW - Virologic response
UR - http://www.scopus.com/inward/record.url?scp=73349101555&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73349101555&partnerID=8YFLogxK
U2 - 10.1097/QAI.0b013e3181b9e94d
DO - 10.1097/QAI.0b013e3181b9e94d
M3 - Article
C2 - 19950432
AN - SCOPUS:73349101555
SN - 1525-4135
VL - 52
SP - 588
EP - 594
JO - Journal of Acquired Immune Deficiency Syndromes
JF - Journal of Acquired Immune Deficiency Syndromes
IS - 5
ER -